StreetInsider.com News Articles

Form 4 MeiraGTx Holdings plc For: May 27 Filed by: Giroux Richard

Thu, 28 May 2026 21:04:00 -0400

si-local-file:///var/storage/secattach/20260528/26569446.html

Form 4 MeiraGTx Holdings plc For: May 27 Filed by: Giroux Richard

Thu, 28 May 2026 21:04:00 -0400

si-local-file:///var/storage/secattach/20260528/26569446.html

H.C. Wainwright Reiterates Buy Rating on MeiraGTx Holdings plc (MGTX)

Tue, 26 May 2026 06:53:31 -0400

H.C. Wainwright analyst Mitchel Kapoor reiterated a Buy rating and $20.00 price target on MeiraGTx Holdings plc (NASDAQ: MGTX).

The analyst commented: "MeiraGTx said the randomized, double-blind, placebo-controlled Phase 2 of AAV2-hAQP1 in grade 2/3 radiation-induced xerostomia (RIX) is closing this month, with 12-month pivotal data on track for 2Q27; if positive, the study could support a Biologics License Application (BLA), potential approval by YE27, and U.S. launch in early 2028. We view the timeline tightening as incrementally key, as the program is moving from enrollment execution to a defined pivotal event. We will be seeking a statistically significant and clinically

Form 4 MeiraGTx Holdings plc For: May 19 Filed by: Forbes Alexandria

Tue, 19 May 2026 21:05:00 -0400

si-local-file:///var/storage/secattach/20260519/26523402.html

Form 4 MeiraGTx Holdings plc For: May 19 Filed by: Forbes Alexandria

Tue, 19 May 2026 21:05:00 -0400

si-local-file:///var/storage/secattach/20260519/26523402.html

Form 144 MeiraGTx Holdings plc Filed by: Forbes Alexandria

Tue, 19 May 2026 21:04:00 -0400

si-local-file:///var/storage/secattach/20260519/26523399.html

Form 144 MeiraGTx Holdings plc Filed by: Forbes Alexandria

Tue, 19 May 2026 21:04:00 -0400

si-local-file:///var/storage/secattach/20260519/26523399.html

MeiraGTx Holdings plc (MGTX) PT Raised to $25 at RBC Capital

Fri, 15 May 2026 07:38:18 -0400

RBC Capital analyst Lisa Walter raised the price target on MeiraGTx Holdings plc (NASDAQ: MGTX) to $25.00 (from $24.00) while maintaining a Outperform rating.

Form 4 MeiraGTx Holdings plc For: May 13 Filed by: Fleck Penny Renee

Thu, 14 May 2026 21:07:00 -0400

si-local-file:///var/storage/secattach/20260514/26497471.html

Form 4 MeiraGTx Holdings plc For: May 13 Filed by: Fleck Penny Renee

Thu, 14 May 2026 21:07:00 -0400

si-local-file:///var/storage/secattach/20260514/26497471.html

Form 3 MeiraGTx Holdings plc For: May 11 Filed by: Fleck Penny Renee

Thu, 14 May 2026 21:01:00 -0400

si-local-file:///var/storage/secattach/20260514/26497457.html

Form 3 MeiraGTx Holdings plc For: May 11 Filed by: Fleck Penny Renee

Thu, 14 May 2026 21:01:00 -0400

si-local-file:///var/storage/secattach/20260514/26497457.html

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Thu, 14 May 2026 16:30:00 -0400

LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company’s Board of Directors approved equity awards to Penny Fleck in connection with her employment with the Company as Chief Development Officer. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c)(4).

Ms. Fleck received equity awards comprised of (i) non-qualified stock options to purchase 100,000 shares of the Company’s ordinary shares with

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Thu, 14 May 2026 16:30:00 -0400

Ms. Fleck received equity awards comprised of (i) non-qualified stock options to purchase 100,000 shares of the Company’s ordinary shares with

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Thu, 14 May 2026 16:30:00 -0400

Ms. Fleck received equity awards comprised of (i) non-qualified stock options to purchase 100,000 shares of the Company’s ordinary shares with

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Thu, 14 May 2026 16:30:00 -0400

Ms. Fleck received equity awards comprised of (i) non-qualified stock options to purchase 100,000 shares of the Company’s ordinary shares with

MeiraGTx Holdings plc (MGTX) Tops Q1 EPS by 5c

Thu, 14 May 2026 08:31:07 -0400

MeiraGTx Holdings plc (NASDAQ: MGTX) reported Q1 EPS of ($0.57), $0.05 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $290 thousand versus the consensus estimate of $19.58 million.

For earnings history and earnings-related data on MeiraGTx Holdings plc (MGTX) click here.

Form 10-Q MeiraGTx Holdings plc For: Mar 31

Thu, 14 May 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260514/26490646.html

Form 10-Q MeiraGTx Holdings plc For: Mar 31

Thu, 14 May 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260514/26490646.html

Form 8-K MeiraGTx Holdings plc For: May 14

Thu, 14 May 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260514/26490432.html

Form 8-K MeiraGTx Holdings plc For: May 14

Thu, 14 May 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260514/26490432.html

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

Thu, 14 May 2026 08:00:00 -0400

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1
Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia
Entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)
Strengthened balance sheet with $100 million financing

LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

Thu, 14 May 2026 08:00:00 -0400

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1
Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia
Entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)
Strengthened balance sheet with $100 million financing

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

Thu, 14 May 2026 08:00:00 -0400

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1
Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia
Entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)
Strengthened balance sheet with $100 million financing

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

Thu, 14 May 2026 08:00:00 -0400

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1
Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia
Entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)
Strengthened balance sheet with $100 million financing